###begin article-title 0
Impaired DNA Replication within Progenitor Cell Pools Promotes Leukemogenesis
###end article-title 0
###begin article-title 1
A Surprising New Path to Tumor Development
###end article-title 1
###begin p 2
###xml 658 665 658 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 1177 1182 <span type="species:ncbi:9606">human</span>
Impaired cell cycle progression can be paradoxically associated with increased rates of malignancies. Using retroviral transduction of bone marrow progenitors followed by transplantation into mice, we demonstrate that inhibition of hematopoietic progenitor cell proliferation impairs competition, promoting the expansion of progenitors that acquire oncogenic mutations which restore cell cycle progression. Conditions that impair DNA replication dramatically enhance the proliferative advantage provided by the expression of Bcr-Abl or mutant p53, which provide no apparent competitive advantage under conditions of healthy replication. Furthermore, for the Bcr-Abl oncogene the competitive advantage in contexts of impaired DNA replication dramatically increases leukemogenesis. Impaired replication within hematopoietic progenitor cell pools can select for oncogenic events and thereby promote leukemia, demonstrating the importance of replicative competence in the prevention of tumorigenesis. The demonstration that replication-impaired, poorly competitive progenitor cell pools can promote tumorigenesis provides a new rationale for links between tumorigenesis and common human conditions of impaired DNA replication such as dietary folate deficiency, chemotherapeutics targeting dNTP synthesis, and polymorphisms in genes important for DNA metabolism.
###end p 2
###begin p 3
The authors show that the replicative competence of normal body cells can influence the rate of outgrowth of cells that carry an oncogene, helping explain a poorly understood aspect of carcinogenesis. 
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b01">1</xref>
###xml 839 840 839 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b01">1</xref>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b02">2</xref>
Despite significant advances in leukemia research, the factors that promote the selection and expansion of mutated cells leading to leukemia are not well known. Leukemias represent abnormal and poorly regulated hematopoiesis, with leukemia stem cells capable of self-renewal as well as the generation of multiple cell types [1]. Acquired mutations contributing to leukemogenesis, including chromosomal translocations that generate oncogenic fusion genes, may need to occur in hematopoietic stem cells (HSCs), as these cells have sufficient lifespan necessary for the acquisition of additional mutagenic hits. Alternatively, it is possible that oncogenic events happen in more committed progenitors, particularly if the mutation confers self-renewal on the cell or if the cell (such as a B cell progenitor) exhibits a sufficient life span [1,2].
###end p 5
###begin p 6
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b03">3</xref>
###xml 450 457 450 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 563 570 563 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 734 735 734 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b03">3</xref>
###xml 783 790 783 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 922 923 922 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b04">4</xref>
###xml 1072 1073 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b05">5</xref>
###xml 1306 1307 1306 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b06">6</xref>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease characterized by excessive proliferation of progenitor cells with massive accumulation of mature myeloid lineage cells. Untreated, the chronic phase is typically followed by an accelerated phase and blast crisis [3]. The t(9:22) Philadelphia chromosome translocation product generating p210 Bcr-Abl is the major cause of CML, and translocations generating either p210 or p190 Bcr-Abl fusions are present in childhood and adult acute lymphoblastic leukemias (ALLs). The CML-associated p210 Bcr-Abl gene is found in myeloid, erythroid, and lymphoid lineage cells in CML patients, suggesting that the translocation originally occurred in a pluripotent stem cell [3]. Recent evidence suggests that while the p210 Bcr-Abl fusion is found in HSC, the leukemia stem cells for both p210- and p190-associated ALLs possess committed B progenitor phenotypes [4]. The Bcr-Abl kinase promotes proliferation and growth factor independence, through the activation of a number of growth factor signaling pathways [5]. In addition, Bcr-Abl expression increases genomic instability, in part by stimulating homologous recombination repair, which can promote survival after DNA damage, while increasing recombination and loss of heterozygosity events [6].
###end p 6
###begin p 7
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b07">7</xref>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b08">8</xref>
###xml 426 430 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 438 442 438 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b09">9</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b10">10</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b11">11</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b12">12</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b13">13</xref>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b14">14</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b14">14</xref>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b16">16</xref>
###xml 1136 1138 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b13">13</xref>
###xml 1139 1141 1139 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b14">14</xref>
###xml 1317 1319 1317 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b17">17</xref>
###xml 1540 1542 1540 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b17">17</xref>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 1153 1161 <span type="species:ncbi:9606">patients</span>
A number of contexts associated with decreased cell cycle progression are, somewhat paradoxically, associated with high rates of tumors. The loss of the E2F1 and E2F2 transcription factors are generally associated with decreased proliferation in vitro and in vivo [7,8], consistent with their roles in promoting the transcription of a variety of genes required for cell cycle progression. Surprisingly, mice with mutations in E2f1 and/or E2f2 genes exhibit significantly increased cancer incidence [9,10]. Until now, the proposed tumor suppressive function of E2F1 and E2F2 has been attributed to decreased E2F-dependent apoptosis, DNA repair, or gene repression (reviewed in [11,12]). In addition, dietary folate deficiency, resulting in impaired DNA replication in cells in vivo, and polymorphisms that reduce dNTP synthesis are associated with increased colon cancer and leukemia rates [13,14]. Previous studies have substantiated that dNTP imbalances caused by folate deficiency or drugs that inhibit dNTP synthesis can increase DNA damage [14-16], and enhanced mutation accumulation is thought to underlie increased tumorigenesis [13,14]. Finally, patients treated with particular chemotherapeutic regimens, such as etoposide with methotrexate, are at increased risk of treatment-related acute myeloid leukemia [17]. Etoposide and methotrexate, which inhibit topoisomerase II and dihydrofolate reductase respectively, are effective inhibitors of DNA replication. Chemotherapeutics such as etoposide promote chromosomal translocations [17], and dNTP imbalances engendered by methotrexate may further promote mutation accumulation. Relevant to the studies presented here, genetic, dietary, and chemotherapeutic inhibitions of the dNTP and folate metabolic pathways are expected to promote replicative stress and DNA damage, leading to checkpoint activation and cell cycle inhibition.
###end p 7
###begin p 8
###xml 309 318 309 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1/E2f2</italic>
###xml 399 402 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
While it is logical that conditions that negatively impact on a cell population could select for mutations conferring resistance, whether contexts of impaired proliferation contribute to tumorigenesis has not been previously demonstrated. We show that impaired DNA replication of hematopoietic progenitors in E2f1/E2f2 mutant mice or mice treated with hydroxyurea (HU) allows Bcr-Abl-expressing and p53-mutated progenitors to outcompete nonmutated cells in the same niche, promoting leukemogenesis.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
The Poorly Replicating E2f1-/-E2f2-/- Progenitor Environment Favors the Competitive Expansion of Bcr-Abl-Expressing Progenitors
###end title 10
###begin p 11
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 92 95 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 99 102 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 130 133 130 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 137 140 137 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 191 195 191 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 197 198 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b07">7</xref>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 285 289 285 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 365 372 365 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b05">5</xref>
###xml 777 784 777 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 961 969 961 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g001">Figure 1</xref>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 437 443 <span type="species:ncbi:9606">humans</span>
###xml 500 505 <span type="species:ncbi:10090">mouse</span>
###xml 906 910 <span type="species:ncbi:10090">mice</span>
DNA replication in bone marrow (BM) progenitor cell populations is severely impaired in E2f1-/-E2f2-/- (DKO) mice, but not in E2f1+/-E2f2+/- mice (phenotypically wild type; henceforth called E2f1+2+), leading to severe hematopoietic deficiencies [7]. We tested the effects of E2f1 and E2f2 mutation on the expansion and leukemogenicity of cells expressing the p190 Bcr-Abl fusion oncogene, which is preferentially associated with ALL in humans [5]. For most experiments, we limited transduction with mouse stem cell viruses (MSCVs) encoding Bcr-Abl and/or green fluorescent protein (GFP) to only a small percentage of progenitors to more accurately reflect the rare occurrence of oncogenic initiating events in a background of unmutated cells, allowing for competition between Bcr-Abl-positive and -negative progenitor cells. The transduced cells were then transplanted into wild-type irradiated recipient mice, and competitive reconstitution was analyzed (see Figure 1 for the experimental design).
###end p 11
###begin p 12
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F1</italic>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 187 188 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 297 305 297 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">2</xref>
###xml 334 342 334 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl-</italic>
###xml 526 530 526 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F1</italic>
###xml 530 531 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 531 532 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 699 703 699 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F1</italic>
###xml 703 704 703 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 704 705 704 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 705 706 705 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 762 771 762 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="sg001">Figure S1</xref>
###xml 892 896 892 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 897 901 897 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 1138 1142 1138 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 1142 1143 1142 1143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1143 1144 1143 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 1144 1145 1144 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1170 1179 1170 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figures 2</xref>
###xml 1182 1183 1182 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">2</xref>
At low transduction efficiencies (less than 5% of transplanted cells expressing Bcr-Abl), we found that Bcr-Abl expression clearly provides a substantial advantage for DKO, but not E2F1+2+ progenitors, as reflected by contributions to peripheral blood cells at 3 wk post-BM transplantation (BMT) (Figure 2A and 2B). The recipients of Bcr-Abl-transduced DKO cells had dramatically increased percentages of B cells and myeloid cells expressing Bcr-Abl. Increased contributions of Bcr-Abl-expressing cells in the DKO relative to E2F1+2+ background were also observed at high infection efficiency, although a modest (but for many recipients, transient) advantage of Bcr-Abl expression was evident among E2F1+2+ cells in terms of contributions to mature blood cells (Figure S1). As a control, we transduced BM progenitors with vector expressing GFP only, and in numerous experiments we found that E2f1/E2f2 loss did not noticeably affect the ability to transduce stem and progenitor populations, as similar short-term and long-term reconstitution of all lineages as determined by GFP expression was observed in recipients of vector-transduced E2f1+2+ and DKO BM progenitors (Figures 2A, 2C, and unpublished data).
###end p 12
###begin p 13
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 354 355 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b18">18</xref>
###xml 531 532 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 537 538 537 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b19">19</xref>
###xml 699 700 699 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 705 706 705 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 711 712 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 748 752 748 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 752 753 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 753 754 753 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 754 755 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 769 777 769 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 939 940 939 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 945 946 945 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 954 962 954 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 1031 1035 1031 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 1035 1036 1035 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1036 1037 1036 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 1037 1038 1037 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1092 1093 1092 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1098 1099 1098 1099 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1393 1397 1393 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 1397 1398 1397 1398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1398 1399 1398 1399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 1399 1400 1399 1400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 518 522 <span type="species:ncbi:10090">mice</span>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
In order to directly determine contributions to hematopoietic progenitor populations, we analyzed BM from the same set of mice for the expression of GFP (vector or Bcr-Abl) in particular progenitor pools. The lineage negative (Lin-) population in the BM expresses low levels of lineage-specific markers, and is thus enriched for progenitor cells. The Lin- Flk2- Sca1+ population is enriched for HSC but will also include short-term progenitors [18]. Of note, while Sca1 is expressed on only about 25% of HSC in BALB/c mice, the Lin- Sca1+ population is substantially enriched for long-term HSC activity in these mice [19]. We observed a dramatic selective advantage for Bcr-Abl expression in the Lin- Flk2- Sca1+ population in the DKO, but not the E2f1+2+, background (Figure 2C, upper right quadrants), correlating with contributions to peripheral blood cells. Of note, a transient advantage within more committed progenitors (such as Lin- Sca1- cells; Figure 2C, lower right quadrants) is often evident for Bcr-Abl expression in E2f1+2+ cells. As we find that c-Kit is down-regulated on Lin- Sca1+ cells post-BMT (unpublished data), we have been unable to further examine Bcr-Abl expression among highly defined HSC. In summary, Bcr-Abl expression provides a dramatic competitive advantage to progenitor cells in the replication-impaired DKO background, but not in the replication-competent E2f1+2+ background.
###end p 13
###begin title 14
The Expression of Bcr-Abl Restores S Phase Progression in DKO Progenitor Cells
###end title 14
###begin p 15
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b20">20</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b21">21</xref>
###xml 667 668 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 672 673 672 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 680 681 680 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 685 686 685 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 998 1000 998 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b20">20</xref>
###xml 1249 1250 1249 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b07">7</xref>
###xml 1464 1465 1464 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b07">7</xref>
###xml 1580 1588 1580 1588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g003">Figure 3</xref>
###xml 1874 1875 1874 1875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b07">7</xref>
###xml 1890 1898 1890 1898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g003">Figure 3</xref>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
The competitive expansion of Bcr-Abl-expressing cells relative to untransduced cells in the DKO background could be the result of overcoming cell cycle defects observed in DKO progenitors. To test this possibility, we assayed the effect of Bcr-Abl expression on S-phase progression rates in DKO progenitor cells using a bromodeoxyuridine (BrdU) pulse-chase method [20]. Two weeks post-BMT, at which point no signs of leukemia development were evident, mice were injected with BrdU and then sacrificed after 2 h. BrdU injection essentially provides a short pulse of the label, since BrdU half-life in vivo is very short [21]. Following flow cytometric isolation of GFP+ Lin- or GFP- Lin- progenitors from the spleen, the average DNA content of BrdU-positive cells was assayed by propidium iodide (PI) intensity profiling. The rates of S phase progression were determined as the shift of the average PI intensity from the middle of S phase toward the G2 peak using formulas described by Begg et al. [20]. Although the calculated progression rates do not provide accurate absolute values for S phase length, since the presumption that the average PI intensity lies in the middle of S phase is not true for DKO cells (which accumulate in early S phase [7]), this method can still accurately analyze the changes of the rates caused by Bcr-Abl expression. Significantly, while S phase progression is substantially slowed in DKO progenitor cells, as previously reported [7], the expression of Bcr-Abl in these cells essentially restored S phase progression to control progression rates (Figure 3). In contrast, the expression of Bcr-Abl had no noticeable effects on S phase progression in wild-type progenitors. In addition, we previously showed that a fraction of DKO BM progenitors appear arrested in S phase, exhibiting S phase DNA content but no detectable BrdU incorporation [7]. As shown in Figure 3A, Bcr-Abl expression in DKO progenitors prevents the accumulation of this S phase-arrested population.
###end p 15
###begin p 16
###xml 274 283 274 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="sg002">Figure S2</xref>
Thus, the competitive advantage provided by Bcr-Abl expression to DKO progenitors appears to derive from restored cell cycle progression. Furthermore, as we find that the expression of Bcl2 does not provide an advantage to DKO progenitors relative to wild-type progenitors (Figure S2), the ability of Bcr-Abl to block apoptosis does not appear to underlie the selective advantage conferred by Bcr-Abl expression in the DKO background, although decreased apoptosis could be a contributing factor.
###end p 16
###begin title 17
The DKO Background Promotes Bcr-Abl-Mediated Leukemogenesis
###end title 17
###begin p 18
###xml 292 299 292 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 425 434 425 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">Figures 4</xref>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">4</xref>
###xml 490 491 490 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 496 497 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 505 514 505 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figures 2</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="sg001">S1</xref>
###xml 575 579 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 579 580 579 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 580 581 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 581 582 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 715 723 715 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">Figure 4</xref>
###xml 863 864 863 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 958 966 958 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">Figure 4</xref>
###xml 1191 1199 1191 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">Figure 4</xref>
###xml 1311 1312 1311 1312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1316 1317 1316 1317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1343 1347 1343 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 1347 1348 1347 1348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1348 1349 1348 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 1349 1350 1349 1350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1362 1370 1362 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">Figure 4</xref>
###xml 1481 1489 1481 1489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
As leukemogenesis appears to require initiating mutations in stem or progenitor cell populations, we addressed whether the greater competitive advantage provided to Bcr-Abl-expressing DKO progenitors translates to increased tumor incidence in transplanted mice. Strikingly, all recipients of Bcr-Abl-transduced DKO progenitors developed rapid pre-B ALL-like disease using both low and high initial transduction efficiencies (Figures 4A and 4B), preceded by rapid increases of peripheral GFP+ B220+ cells (Figures 2A and S1). In contrast, only about half of the recipients of E2f1+2+ cells transduced at high efficiency, and none of the recipients at low transduction efficiency, developed leukemia (also pre-B ALL; Figure 4). For leukemias arising in both genetic backgrounds, leukemic infiltrates were evident in spleen, liver, and lung, and peripheral blood GFP+ cells expressed low B220, exhibiting a large, immature morphology with pale-staining nuclei (Figure 4C and unpublished data). Leukemia cells in the spleen and BM were mostly negative for the Lin markers GR-1, Ter119, CD4, and CD3 (unpublished data), expressing from undetectable to low B220 levels depending on the leukemias (Figure 4C; examples shown express little to no B220). Interestingly, we consistently observed a greater fraction of Sca1+CD34+ cells in DKO relative to E2f1+2+ leukemias (Figure 4C), consistent with the early advantage provided by Bcr-Abl expression in DKO progenitor-enriched populations (Figure 2C).
###end p 18
###begin title 19
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 5 6 5 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 6 7 6 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
E2f1+2+ Competitors Effectively Suppress Leukemia Development by Bcr-Abl-Expressing DKO Progenitors
###end title 19
###begin p 20
###xml 230 239 230 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1/E2f2</italic>
###xml 405 409 405 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 409 410 409 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 448 455 448 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 570 579 570 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">Figures 4</xref>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">4</xref>
###xml 590 594 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 594 595 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 595 596 595 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 596 597 596 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 756 765 756 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figures 2</xref>
###xml 768 769 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">2</xref>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="sg001">S1</xref>
###xml 823 831 823 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 865 872 865 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1135 1139 1135 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 1144 1148 1144 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
While leukemogenesis correlates with the ability of Bcr-Abl-expressing cells to competitively expand within progenitor pools, based on increased leukemia rates alone we cannot distinguish whether or not cell autonomous effects of E2f1/E2f2 loss, such as accelerated mutagenesis or decreased apoptosis, are the major factors underlying increased leukemia rates. To directly address this issue, we included E2f1+2+ untransduced competitor cells with Bcr-Abl-transduced DKO progenitors; amazingly, these competitors were able to almost completely eliminate leukemogenesis (Figures 4A and 4B). E2f1+2+ competitors also substantially reversed the selective advantage conferred by Bcr-Abl expression in the DKO background as reflected in peripheral blood cells (Figures 2A, 2B, and S1) and within stem cell-enriched populations (Figure 2C). Similarly, transplantation of Bcr-Abl-transduced DKO progenitors into sublethally irradiated recipients resulted in the rebound of host (wild-type) hematopoiesis and complete prevention of leukemias (unpublished data). Thus, enhanced leukemogenesis is not primarily due to cell autonomous effects of E2f1 and E2f2 loss, but most likely results from the poor ability of DKO progenitor cells to compete with Bcr-Abl-expressing DKO progenitors.
###end p 20
###begin p 21
###xml 74 81 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 209 216 209 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 280 287 280 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 570 574 570 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 574 575 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 575 576 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 576 577 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 620 627 620 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 627 628 627 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 665 674 665 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">Figures 4</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="sg001">S1</xref>
Importantly, these results suggest that the failure of many recipients of Bcr-Abl-transduced E2f1+2+ (particularly at low transduction efficiency) to develop leukemia was not due to our inability to introduce Bcr-Abl into the appropriate progenitor cells, but to the inability of Bcr-Abl+ progenitors to be maintained in the face of replication competent competitors. Finally, while it remains formally possible that DKO stem/progenitor cells home poorly to BM niches and that Bcr-Abl restores homing to DKO progenitors, the fact that a low percentage of cotransplanted E2f1+2+ BM can reverse the selective expansion of Bcr-Abl+ DKO progenitors and leukemogenesis (Figures 4 and S1) strongly argues against a role for differential homing in genotype-dependent leukemia rates.
###end p 21
###begin p 22
In summary, a DKO progenitor pool promotes Bcr-Abl-dependent leukemogenesis due to the inability of untransduced DKO progenitors to provide effective competition. The ability of Bcr-Abl to restore S phase progression to replication impaired DKO progenitors most likely underlies the competitive advantage provided by Bcr-Abl specifically within the DKO background.
###end p 22
###begin title 23
HU Promotes the Competitive Expansion of Bcr-Abl-Expressing Blood Progenitors Ex Vivo
###end title 23
###begin p 24
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b22">22</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b23">23</xref>
###xml 778 786 778 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g005">Figure 5</xref>
###xml 869 876 869 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 876 877 876 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1123 1131 1122 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g005">Figure 5</xref>
###xml 1224 1231 1222 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1231 1232 1229 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1543 1551 1540 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g005">Figure 5</xref>
###xml 1679 1687 1676 1684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g005">Figure 5</xref>
###xml 1821 1823 1818 1820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b24">24</xref>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
###xml 1753 1761 <span type="species:ncbi:9606">patients</span>
In order to further explore the generality of the selection for Bcr-Abl-expressing cells under conditions of impaired DNA replication as well as to examine Bcr-Abl-mediated leukemogenesis in a more clinically relevant context, we asked how the suppression of proliferation within hematopoietic progenitor pools during treatment of mice with HU, an inhibitor of ribonucleotide reductase, affects Bcr-Abl-dependent competition within wild-type BM. HU has been used for over 40 y as a cytostatic drug [22]. HU-induced dNTP depletion results in replication stalling and the activation of checkpoint pathways [23]. We initially asked whether HU treatment creates a poorly competitive environment that favors the expansion of Bcr-Abl-expressing blood progenitors ex vivo. As shown in Figure 5A, HU differentially affected Bcr-Abl- and vector-expressing progenitors, allowing Bcr-Abl+ cells to competitively expand. In fact, while the expansion of vector-expressing progenitors was almost completely inhibited by all concentrations of HU used, Bcr-Abl-expressing progenitors continued expanding at doses ranging from 5 to 25 muM (Figure 5A, lower panels). Higher doses of 50 and 100 muM HU did effectively inhibit the expansion of Bcr-Abl+ progenitors, indicating that the advantage provided by Bcr-Abl expression during HU treatment is relative but not absolute. While Bcr-Abl expression alone provided a modest advantage to wild-type progenitors in culture, 5 to 25 muM HU treatment conferred an even greater advantage to Bcr-Abl-expressing cells (Figure 5A, upper panel). Furthermore, as determined by GFP expression levels, HU selects for cells expressing higher levels of Bcr-Abl (Figure 5B). Notably, increased Bcr-Abl expression is commonly observed in patients during CML progression from chronic phase to blast crisis [24].
###end p 24
###begin title 25
HU Treatment Provides a Competitive Advantage to Bcr-Abl-Expressing Progenitors In Vivo
###end title 25
###begin p 26
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b22">22</xref>
###xml 340 347 340 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 347 348 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 389 390 389 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 395 396 395 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 509 517 509 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g006">Figure 6</xref>
###xml 578 579 578 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 584 585 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 645 652 645 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 652 653 652 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 657 658 657 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 663 664 663 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1090 1097 1090 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1097 1098 1097 1098 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 698 702 <span type="species:ncbi:10090">mice</span>
###xml 732 736 <span type="species:ncbi:10090">mice</span>
Mice were transplanted with MSCV-p190 Bcr-Abl-transduced BALB/c BM progenitor cells, and half of the recipients were switched to water containing HU (20 mg/kg/d; similar to doses used clinically for cytoreduction [22]) at 2 wk post-BMT. Strikingly, by 5 and 8 d after switching recipient mice to HU, a substantial competitive advantage for Bcr-Abl+ cells within the progenitor-enriched Lin- Sca1+ population was evident, while a similar selection for Bcr-Abl expression was not observed without HU treatment (Figure 6A). Note that about two-thirds of the progenitor-enriched Lin- Sca1+ cells expressed Bcr-Abl in HU-treated mice, while very few Bcr-Abl+ Lin- Sca1+ cells were detected in untreated mice, despite the fact that these mice were transplanted with the same pool of transduced BM progenitors. The rapid competitive advantage provided by Bcr-Abl specifically following HU treatment in vivo, together with the almost immediate selection for Bcr-Abl expression by HU ex vivo, argues that HU-induced mutagenesis does not account for the effects of HU on the competitive expansion of Bcr-Abl+ progenitors.
###end p 26
###begin p 27
###xml 198 206 198 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g003">Figure 3</xref>
###xml 428 436 428 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g006">Figure 6</xref>
To understand why Bcr-Abl provides such an advantage specifically following HU treatment, we analyzed cell cycle progression in Bcr-Abl-expressing progenitors in vivo using the same method used for Figure 3. While HU decreased the percentage of cells undergoing DNA synthesis and increased the length of S phase, Bcr-Abl expression resulted in more normal S phase progression in leukocytic progenitors in HU-treated recipients (Figure 6B). This result provides a mechanistic insight into why HU treatment improves the competitive expansion of Bcr-Abl-expressing progenitors in vivo and ex vivo: While HU impedes the proliferation of competing progenitors, Bcr-Abl overcomes this block. In contrast, Bcr-Abl expression does not appear to affect DNA replication in untreated progenitors, and thus Bcr-Abl expression does not provide an apparent competitive edge without HU.
###end p 27
###begin title 28
HU Treatment Accelerates and Increases the Penetrance of Bcr-Abl-Mediated Leukemias
###end title 28
###begin p 29
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 158 165 158 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 330 331 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 646 654 634 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g007">Figure 7</xref>
###xml 701 708 689 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 708 709 696 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 727 728 715 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 801 808 789 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1051 1059 1039 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g007">Figure 7</xref>
###xml 1277 1284 1265 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1284 1285 1272 1273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1310 1318 1298 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g006">Figure 6</xref>
###xml 1576 1580 1564 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2</italic>
###xml 1580 1583 1568 1571 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1665 1674 1653 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="sg003">Figure S3</xref>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 782 786 <span type="species:ncbi:10090">mice</span>
###xml 1011 1015 <span type="species:ncbi:10090">mice</span>
###xml 1163 1168 <span type="species:ncbi:9606">human</span>
###xml 1584 1588 <span type="species:ncbi:10090">mice</span>
We addressed whether HU treatment of mice with Bcr-Abl+ progenitors promotes leukemogenesis in vivo. For each experiment, aliquots from a single pool of MSCV-Bcr-Abl (or vector)-transduced BALB/c BM stem cells were transplanted into multiple syngeneic recipients. For all recipients, approximately3% of peripheral B cells were GFP+ at 2 wk post-BMT, at which point half of the mice were switched to water containing HU. By treating with HU starting 2 wk post-BMT, potential effects of HU on retroviral infection efficiency or homing to BM niches are avoided. Strikingly, all of the HU-treated mice developed a pre-B ALL-like disease within 2 mo (Figure 7A) preceded by increases in the percentages of Bcr-Abl+ cells in the B220+ subset (unpublished data). In contrast, mock-treated mice that received Bcr-Abl-transduced stem cells developed leukemia with much lower penetrance (3 of 8) and longer latency periods. HU treatment also enhanced leukemogenesis induced by p210 Bcr-Abl, although interestingly, these mice all succumbed to CML-like disease (Figure 7B). Thus, in our model system, p190 Bcr-Abl causes B-ALL and p210 causes CML, thus closely modeling the human diseases caused by the respective translocation products. Given that HU treatment promotes the expansion of Bcr-Abl+ progenitors within 5 d (Figure 6A), it is improbable that HU-promoted mutagenesis alone accounts for more rapid disease, although increased mutation accumulation may be a contributing factor. Furthermore, as HU similarly promotes leukemogenesis in analogous experiments using donor BM from Rag2-/- mice, in which case mature T and B cells were nearly undetectable in recipients (Figure S3), HU-mediated increases in Bcr-Abl-dependent leukemogenesis does not appear to result from immunosuppression.
###end p 29
###begin p 30
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 95 96 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 171 180 171 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g007">Figures 7</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="sg004">S4</xref>
###xml 674 675 674 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 683 690 683 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 690 691 690 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 827 835 827 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g007">Figure 7</xref>
###xml 877 878 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 881 882 881 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 928 935 928 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1083 1092 1083 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="sg005">Figure S5</xref>
###xml 1141 1148 1141 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1148 1149 1148 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
Leukemic p190 Bcr-Abl recipient mice exhibited massive increases in pre-B-like large B220+ CD43+ cells, high leukocyte blast counts in peripheral blood, and splenomegaly (Figures 7C and S4). Pathological characterization of spleens and other tissues determined that the lymphoproliferative diseases arising in all HU and the three non-HU-treated mice were large cell leukemias, with frequent involvement of liver, lung, and spleen (unpublished data). Spleens contained a mixture of leukemic cells, with most exhibiting lymphoid characteristics and a subset exhibiting a myeloid phenotype (unpublished data). For most HU (relative to non-HU)-treated mice, the predominant GFP+ (i.e., Bcr-Abl+) population in the BM and spleen contained a more substantial subpopulation of cells expressing the progenitor markers c-Kit and CD34 (Figure 7D). We transplanted spleen or BM cells (103-105) from morbid leukemic HU- and non-HU-treated Bcr-Abl BMT recipients into BALB/c recipients, and most recipients for both groups developed leukemia, underscoring the malignant nature of the leukemias (Figure S5). Thus, by providing a competitive advantage to Bcr-Abl+ progenitor cells (as shown ex vivo and in vivo), HU treatment promotes Bcr-Abl-mediated ALL and CML.
###end p 30
###begin title 31
The Inhibition of p53 Provides a Competitive Advantage to DKO BM Progenitors
###end title 31
###begin p 32
###xml 240 243 240 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 323 326 323 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b25">25</xref>
###xml 460 463 460 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 795 804 795 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1/E2f2</italic>
###xml 962 964 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b26">26</xref>
###xml 1170 1178 1170 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g008">Figure 8</xref>
###xml 293 298 <span type="species:ncbi:9606">human</span>
###xml 467 472 <span type="species:ncbi:9606">human</span>
###xml 1080 1084 <span type="species:ncbi:10090">mice</span>
While our experiments provide strong evidence that backgrounds of impaired DNA replication enhance the competitive expansion of Bcr-Abl-expressing cells, we wanted to test if this phenomenon can be applicable to other oncogenic events. The p53 tumor suppressor gene is mutated in over half of human tumors, and mutation of p53 has been shown to disrupt checkpoints that prevent cell cycle progression in the face of various cellular stresses [25]. Mutation of p53 in human cancers frequently results in the expression of a dominant negative mutant p53 protein (DNp53) that forms inactive multimers with wild-type p53. Given the known ability of DNp53 to alleviate checkpoint-dependent cell cycle arrests, we asked whether the expression of DNp53 (175H) could provide a competitive advantage for E2f1/E2f2 mutant progenitor expansion. In addition, we engineered a retrovirus to express the oligomerization domain of p53 (DDp53), which also inhibits p53 activity [26]. Strikingly, MSCV-mediated expression of DNp53 or DDp53 in hematopoietic progenitors from DKO, but not wild-type, mice resulted in a dramatic selective advantage for these cells after only 2 wk post-BMT (Figure 8A). Again, the percentages of peripheral blood cells expressing vector were very similar for wild-type and DKO cells. Thus, the inhibition of p53 provides a competitive advantage during hematopoiesis in DKO, but not wild-type, BM.
###end p 32
###begin p 33
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 35 37 35 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b27">27</xref>
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 123 132 123 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1/E2f2</italic>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b28">28</xref>
###xml 292 295 292 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 295 298 295 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 301 302 301 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 320 323 320 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 323 326 323 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 329 330 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 433 441 433 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g008">Figure 8</xref>
###xml 461 464 461 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 565 568 565 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 568 571 568 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 574 575 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 740 744 740 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 744 745 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 745 746 745 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 746 747 746 747 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 761 769 761 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g008">Figure 8</xref>
###xml 852 860 852 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 893 896 893 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 896 899 896 899 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 938 941 938 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 941 944 941 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1024 1033 1024 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1/E2f2</italic>
We used genetic disruption of p53 [27] as an alternative to retroviral DNp53 expression. We bred the p53 mutation into the E2f1/E2f2 mutant and BALB/c backgrounds together with a ubiquitously expressed GFP transgene [28]. In competitive BMT experiments using wild-type BM in competition with p53-/-GFP+ BM (93:7 ratio), p53-/-GFP+ BM contributions to hematopoiesis were similar to its percentage within the original BM transplanted (Figure 8B), indicating that p53 mutation does not provide an immediate competitive advantage during hematopoiesis. In contrast, DKO/p53-/-GFP+ BM progenitors exhibited significant competitive expansion relative to DKO progenitors, and this competitive expansion was completely abrogated by the inclusion of E2f1+2+ competitors (Figure 8B; compare second and third columns). Thus, as in the Bcr-Abl experiments shown in Figure 2, the increased expansion of DKO/p53-/- cells in a DKO background relative to p53-/- cells in a wild-type background is not due to cell autonomous contributions of E2f1/E2f2 loss, but instead to the poor competition provided by DKO hematopoiesis.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b29">29</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b30">30</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b33">33</xref>
Given that deregulated cell cycling is considered a hallmark of tumorigenesis [29], it is natural to assume that contexts that promote proliferation would promote cancer. Studies in search of connections between genetic polymorphisms, dietary factors, and environmental exposures that predispose to cancer are often predicated on the assumption that increased cancer rates in part result from the enhancement of proliferation by these conditions [30-33]. We show that the opposite can be true. Our data indicate that the reduced ability of progenitor cell pools to proliferate actually promotes tumorigenesis, in that cells acquiring mutations that improve proliferation outcompete poorly replicating competitors. In contrast, a replication-competent pool is inherently tumor-suppressive, and otherwise oncogenic mutations may not be favored.
###end p 35
###begin p 36
###xml 396 399 396 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f</italic>
###xml 670 677 670 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 677 678 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1173 1182 1173 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1/E2f2</italic>
###xml 1245 1248 1245 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F</italic>
###xml 1305 1314 1305 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1/E2f2</italic>
###xml 1324 1328 1324 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 1328 1329 1328 1329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1329 1330 1329 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 1330 1331 1330 1331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
We have shown that within a wild-type, healthy progenitor cell pool, Bcr-Abl expression or p53 inhibition does not provide an apparent selective advantage. In contrast, in contexts of impaired DNA replication of blood progenitors, expression of Bcr-Abl or inhibition of p53 provides an immediate advantage within progenitor pools. The expression of Bcr-Abl bypasses the S phase blocks imposed by E2f mutation or HU treatment, consistent with the known ability of Bcr-Abl to abrogate cell cycle checkpoints. As Bcr-Abl expression provides an immediate competitive advantage following HU treatment ex vivo, the advantage appears to result from the better proliferation of Bcr-Abl+ cells relative to untransduced peers, not effects of HU on mutagenesis or the immune system, or other potential complications found in vivo. Most importantly, replication-impaired contexts (both genetic and chemotherapeutic) can substantially promote Bcr-Abl-dependent leukemias. That Bcr-Abl-expressing cells with restored S phase progression outcompete untransduced cells with highly impaired replication provides a logical explanation for the promotion of leukemogenesis by HU treatment and E2f1/E2f2 loss. Indeed, the promotion of Bcr-Abl-dependent leukemias by E2F mutation is not due to cell autonomous contributions of E2f1/E2f2 loss, as E2f1+2+ competitors virtually eliminate leukemias resulting from Bcr-Abl expression in DKO progenitors. Thus, healthy competitors are potently tumor-suppressive.
###end p 36
###begin p 37
###xml 374 382 374 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g009">Figure 9</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b34">34</xref>
The presented results support a model whereby the reduced proliferation of blood progenitors provides a powerful selection for oncogenic mutations that improve cell cycle progression. In essence, impeded proliferation of progenitor cells provides for poor competition, promoting the expansion of progenitors that acquire oncogenic mutations which relieve cell cycle blocks (Figure 9). In addition, the ability of some oncogenic mutations to impede apoptosis resulting from checkpoint activation might further contribute to a net competitive advantage. It has been previously proposed that carcinogen-mediated inhibition of cell survival or proliferation can select for oncogenically mutated cells resistant to these conditions ([34] and references therein). Analogously, we show that conditions that impair DNA replication in the entire population of progenitor cells select for oncogenic mutations that initiate tumorigenesis. In contrast, oncogenic mutations prove less advantageous or even disadvantageous in a normal hematopoietic system, as cell cycle progression in the progenitor pool is already efficient, and checkpoints should not be activated. Finally, contexts that involve nucleotide deprivation and DNA damage, and thus impeded DNA replication, may enhance mutation accumulation, and mutator phenotypes should synergize with poor competition to promote tumorigenesis. Thus, these conditions provide not only an increased chance for the acquisition of initiating mutations, but also a poorly competitive environment that favors the expansion of these oncogenically mutated cells. In this regard, it is unlikely that all conditions that globally impair cell cycle progression in a stem cell pool will promote tumorigenesis, particularly if these impaired contexts cannot be easily overcome by oncogenic mutation or do not sufficiently promote mutation accumulation. Moreover, while impaired replication can clearly select for the expression of oncogenes such as Bcr-Abl and DNp53, other oncogenic events (like Bcl2 overexpression) may not be selected for and may even be selected against.
###end p 37
###begin p 38
###xml 189 196 189 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b35">35</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b37">37</xref>
###xml 277 284 277 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 697 704 697 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b38">38</xref>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b40">40</xref>
###xml 1028 1030 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b36">36</xref>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b37">37</xref>
###xml 1154 1156 1154 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b41">41</xref>
###xml 1157 1159 1157 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b43">43</xref>
###xml 1175 1182 1175 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1182 1183 1182 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1273 1280 1273 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1280 1281 1280 1281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1289 1291 1289 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b44">44</xref>
###xml 1675 1682 1675 1682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1682 1683 1682 1683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1710 1717 1710 1717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1717 1718 1717 1718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1006 1012 <span type="species:ncbi:10090">murine</span>
###xml 1148 1152 <span type="species:ncbi:10090">mice</span>
The low leukemia incidence that we observed in the replication competent-backgrounds may seem at odds with previous reports of efficient induction of CML-like disease in recipients of MSCV-Bcr-Abl-transduced BM cells using high-efficiency infections [35-37]. So why would MSCV-Bcr-Abl transduction result in rapid and penetrant onset of leukemia with high- but not low-efficiency infection, given that normal hematopoietic stem and progenitor cells, and thus healthy competitors, are still present in both cases? One possibility is that the resulting high percentage of cells expressing Bcr-Abl could result in substantial autocrine stimulation, which may not reflect the normal context of a rare Bcr-Abl fusion event. Indeed, expression of Bcr-Abl in cytokine-dependent cell lines leads to growth factor-independent proliferation associated with autocrine production of interleukin-3 (IL-3) and granulocyte/monocyte-colony stimulating factor [38-40], and increased levels of IL-3 are detected in serum in murine models of CML [36,37]. Importantly, retroviral expression of IL-3 by BM cells is sufficient to induce a myeloproliferative syndrome in mice [41-43]. Furthermore, Bcr-Abl+ cells secrete inhibitors of normal hematopoiesis that induce apoptosis in normal but not Bcr-Abl+ cells [44]. Autocrine stimulation by Bcr-Abl-expressing cells and inhibition of normal hematopoiesis should have a far greater impact when a large percentage of cells express Bcr-Abl, as compared to the physiological context of an initiating mutation leading to the expression of the oncogene in a single clone. Nonetheless, these activities could still be very relevant to the progression of Bcr-Abl+ leukemias, in that once a Bcr-Abl+ clone has reached some critical mass, the clone may promote its own competitive expansion even in the face of normal hematopoietic competitors. Finally, high-efficiency transduction of progenitors should increase the chance of secondary mutations that promote Bcr-Abl-dependent leukemogenesis, including gene alterations mediated by retroviral integrations.
###end p 38
###begin p 39
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 382 389 382 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 515 522 515 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 638 645 638 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 645 646 645 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 790 797 790 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 797 798 797 798 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 847 854 847 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 856 864 856 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IgH-Bcl2</italic>
###xml 870 878 870 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LMO2-TCR</italic>
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b45">45</xref>
###xml 1130 1137 1130 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1222 1224 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b46">46</xref>
###xml 1334 1341 1334 1341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 1063 1069 <span type="species:ncbi:9606">people</span>
###xml 1186 1192 <span type="species:ncbi:9606">people</span>
An important point is that most of the recipients of control (E2f1+2+ or wild-type without HU) progenitors transduced with Bcr-Abl did not develop leukemia. Indeed, for surviving mice, GFP expression in peripheral blood became undetectable (unpublished data), indicating that Bcr-Abl expression is disfavored in stem cell pools in the long-term. The facts that (1) the same pool of Bcr-Abl-transduced BM progenitors was transferred into recipients that subsequently were mock- or HU-treated, and (2) all HU-treated Bcr-Abl recipients rapidly developed leukemia, indicate that most of the nonleukemic mice in the control group did receive Bcr-Abl+ progenitors capable of causing leukemia, but that these cells were not maintained. In contrast, HU treatment clearly promoted the expansion of Bcr-Abl+ cells, stimulating leukemogenesis. Analogously, Bcr-Abl, IgH-Bcl2, and LMO2-TCR translocations are frequently found in nonleukemic individuals who do not subsequently develop leukemias [45]. Based in part on the detection of Bcr-Abl in peripheral blood of healthy people for several months to years, an argument has been made that Bcr-Abl translocations must occur frequently in HSCs of people that never develop leukemia [46]. In light of the data presented here, we suggest that the relative inability of progenitor cells possessing Bcr-Abl translocations to competitively expand and to acquire additional mutations under most contexts limits the development of leukemia.
###end p 39
###begin p 40
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b14">14</xref>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b47">47</xref>
###xml 1084 1091 1084 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1091 1092 1091 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 155 160 <span type="species:ncbi:9606">human</span>
Our result that HU promotes Bcr-Abl-dependent leukemias may seem surprising, given that HU is used for cytoreduction of CML cells in patients. However, in human disease the leukemic cells are already established and dominant, while our experiments are more relevant to the context of leukemia initiation. Thus, our use of HU may be less pertinent to the use of this drug to treat CML, but can be viewed as a general means to suppress S phase progression in the hematopoietic system, which is relevant to the effects of clinically used drugs or other conditions that inhibit DNA replication in progenitor populations. Indeed, a number of contexts that have been presumed or demonstrated to reduce dNTP production are associated with increased cancer rates, including folate deficiency [14] and polymorphisms resulting in decreased thymidylate synthase expression [47]. These contexts of dNTP restriction are thought to promote cancer in part by increasing mutation rates, and our results suggest that poorly competitive stem cell pools also play an important role. While links between Bcr-Abl+ CML or ALL incidence and dietary variables or polymorphisms affecting dNTP metabolism have not been sufficiently examined, based on our demonstration that the inhibition of dNTP synthesis by HU promotes Bcr-Abl-dependent leukemias, such studies are warranted.
###end p 40
###begin p 41
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b15">15</xref>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b16">16</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b48">48</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b49">49</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b50">50</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b48">48</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b51">51</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b17">17</xref>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
HU induces replication-associated double-stranded DNA breaks in cultured cells [15,16], although whether HU induces DNA damage or mutagenesis in vivo is still unresolved. Long-term treatment of sickle cell anemia patients with HU does not result in increased mutation rates or cancer formation [48]. However, some studies have found an association between cytoreductive HU treatment of myeloproliferative disorders and the development of acute leukemias, including a high proportion with 17p deletion [49,50]. Still, while commonly used chemotherapeutic antimetabolites such as HU and methotrexate do not appear to be substantially leukemogenic when used as single agents [48,51], combinations of antimetabolites with etoposide are associated with higher incidences of treatment-related leukemias relative to etoposide alone [17]. While clinical experiences are insufficiently controlled to conclude that antimetabolite therapies contribute to secondary leukemias, our demonstration that a chemotherapeutic agent that inhibits dNTP synthesis can promote leukemia suggests that this issue needs to be further addressed in the clinic. The inhibition of DNA replication by antimetabolites may promote the competitive expansion of progenitor cells acquiring etoposide-induced oncogenic mutations, much as HU promotes the expansion of Bcr-Abl-expressing progenitors. Thus, conditions that generally impair DNA replication, such as drugs that inhibit dNTP synthesis, may function as tumor promoters for oncogenically initiated cells by creating a poorly competitive environment. This view contrasts with the generally described function of tumor promoters as enhancers of proliferation.
###end p 41
###begin p 42
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 199 203 199 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b11">11</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b12">12</xref>
###xml 325 328 325 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 345 354 345 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1/E2f2</italic>
###xml 414 417 414 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f</italic>
###xml 448 457 448 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1/E2f2</italic>
###xml 522 525 522 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f</italic>
###xml 675 679 675 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 683 687 683 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
###xml 566 571 <span type="species:ncbi:10090">mouse</span>
###xml 874 879 <span type="species:ncbi:9606">human</span>
Finally, while numerous properties of E2F1 and E2F2, including gene repression and the promotion of apoptosis and DNA repair, have been suggested to underlie observed increases in tumors in E2f1 and E2f2 mutant mice (reviewed in [11,12]), we demonstrate that the promotion of Bcr-Abl-dependent leukemias and the expansion of p53 mutant cells by E2f1/E2f2 disruption result from non-cell autonomous consequences of E2f loss. According to our model, E2f1/E2f2 mutations at least in part predispose mice to tumors, since the E2f genes are disrupted in all cells in the mouse, thus providing a poorly competitive progenitor population. In contrast, loss-of-function mutations in E2f1 or E2f2 in an individual cell would not be expected to provide an advantage to the cell, and thus would not contribute to tumorigenesis, thus perhaps explaining the paucity of such mutations in human tumors. Poor competition should select for oncogenic mutations only when the entire population of competing cells are similarly debilitated.
###end p 42
###begin p 43
In summary, we have demonstrated that impaired DNA replication in hematopoietic progenitor pools contributes to a powerful selection for mutations (such as Bcr-Abl translocation) that improve cell cycle progression, providing a selective advantage over the poor competition offered by replication-debilitated progenitors and thus promoting leukemogenesis. As cancer development has attributes clearly reminiscent of Darwinian evolution, it is logical that it should become easier for a mutant cell clone to be the "fittest" as the quality of the competition declines. Thus, as with the natural selection of species, poor fitness selects for adaptive mutations in stem cell pools.
###end p 43
###begin title 44
Materials and Methods
###end title 44
###begin title 45
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 45
###begin p 46
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b52">52</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b53">53</xref>
###xml 136 139 136 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 139 142 139 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 309 312 309 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 221 236 <span type="species:ncbi:10090">transgenic mice</span>
###xml 443 448 <span type="species:ncbi:10090">mouse</span>
The generation of the E2f1 and E2f2 mutant mice (backcrossed seven times into BALB/c) has been previously described [52,53]. BALB/c and p53-/- mice were purchased from Jackson Labs (Bar Harbor, Maine, United States). GFP transgenic mice were the generous gift of Dr. Brian Schaefer, and were backcrossed with p53 mutation into the BALB/c background. The University of Colorado Health Sciences Center Animal Care and Use Committee approved all mouse experiments.
###end p 46
###begin title 47
Retroviral constructs
###end title 47
###begin p 48
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcl2</italic>
###xml 121 125 <span type="species:ncbi:23211">Pear</span>
The retroviral MSCV-iresGFP vectors expressing either p190 or p210 Bcr-Abl were provided by Drs. Zhonghan Dai and Warren Pear. MSCV-Bcl2-iresGFP was provided by Dr. Scott Lowe. To construct similar retroviral vectors expressing DNp53 and DDp53, the p53Arg175His cDNA fragment from plasmid pCMV-NEO pC53-175 (provided by Dr. Bert Vogelstein) and DDp53 cDNA from pLXSNp53DD (provided by Dr. Xiao-Fan Wang) were cloned into the MSCV-iresGFP vector.
###end p 48
###begin title 49
Retroviral transduction and bone marrow transplantation
###end title 49
###begin p 50
###xml 245 249 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 249 250 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 250 251 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 451 452 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1267 1268 1254 1255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1385 1392 1372 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1414 1422 1401 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g005">Figure 5</xref>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 567 573 <span type="species:ncbi:9913">bovine</span>
###xml 633 639 <span type="species:ncbi:9913">bovine</span>
###xml 692 697 <span type="species:ncbi:9606">human</span>
###xml 754 759 <span type="species:ncbi:9606">human</span>
###xml 827 832 <span type="species:ncbi:10090">mouse</span>
###xml 1173 1177 <span type="species:ncbi:10090">mice</span>
MSCV viruses were prepared by transient transfection of Phoenix-E cells together with pCL-Eco, and titered on fibroblasts using GFP as the marker, so that similar multiplicities of infection for oncogene and vector viruses were used. Donor DKO, E2f1+2+, or wild-type mice were injected intraperitoneally with 100 mg/kg 5-fluorouracil (Sigma, St. Louis, Missouri, United States) 3 d prior to BM harvest. Harvested donor BM cells were enriched for c-Kit+ cells by MACS (Miltenyi Biotec, Bad Gladbach, Germany) and then cultured overnight in IMDM plus 15% defined fetal bovine serum (HyClone, South Logan, Utah, United States) and 0.1% bovine serum antigen (Sigma), with the cytokines 100 ng/ml human stem cell factor (gift from Dr. Chris Hogan), 100 ng/ml human IL-11 (PeproTech, Rocky Hill, New Jersey, United States),1.5 ng/ml mouse IL-3 (PeproTech), and 100 ng/ml hIL-6 (PeproTech). Cells were transduced with MSCV-containing supernatants (approximately1/5 volume) supplemented with 6 mug/ml Polybrene (Sigma) for 6 h. Cells were then transplanted intravenously into lethally (1,200 Rads for E2F experiments) or sublethally (600 Rads for HU experiments) irradiated BALB/c mice. A subset of the transduced cells was further cultured for 2 d, and the percentage of GFP+ cells was determined by flow cytometry in order to determine the initial infection efficiency. Ex vivo culturing of Bcr-Abl-transduced cells for Figure 5 was performed under the same culture conditions.
###end p 50
###begin title 51
Flow cytometry and cell cycle analysis
###end title 51
###begin p 52
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1217 1218 1215 1216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1225 1226 1223 1224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1255 1256 1253 1254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1266 1267 1264 1265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1302 1310 1300 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g003">Figure 3</xref>
###xml 1317 1318 1315 1316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1323 1331 1321 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g006">Figure 6</xref>
###xml 1461 1462 1459 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b07">7</xref>
###xml 1463 1465 1461 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b20">20</xref>
###xml 389 394 <span type="species:ncbi:10090">mouse</span>
###xml 971 975 <span type="species:ncbi:10090">mice</span>
Single-cell suspensions were washed in PBS containing 5% FBS (FBS-PBS). About 106 cells were stained in 20 mul of antibody solution (1:100 dilution of each antibody) for 30 min at room temperature. Cells were washed once with 1 ml of FBS-PBS and resuspended in 400 mul of PBS for flow cytometric analysis. The following PharMingen (San Diego, California, United States) antibodies against mouse were used: phycoerythrin (PE)-linked anti-B220, PE-anti-Ter119, PE-anti-GR-1, PE-anti-CD3, PE-anti-CD4, PE-anti-Flk2/Flt3, and PE-anti-CD43; and allophycocyanin (APC)-linked anti-B220, APC-anti-Thy1.2, and APC-anti-CD117; and biotin-linked anti-GR-1, biotin-anti-CD34, biotin-anti-IgM, and PE-cyanine (PE-Cy7)-linked anti-biotin. APC-anti-Sca1 antibodies were purchased from eBioscience (San Diego, California, United States). Fluorescence was detected with a Cytomics FC 500 (Beckman Coulter, Allendale, New Jersey, United States) cytometer. For BrdU incorporation analyses, mice were injected intraperitoneally with BrdU (1 mg per 25 g of body weight; Roche, Indianapolis, Indiana). After 2 h, pooled spleen and BM cells were purified using a MoFlo (Cytomation, Fort Collins, Colorado, United States) cell sorter for GFP+ or GFP- subsets of progenitors: B220+ plus GR-1+ (B-cell and myeloid lineages) for Figure 3 or Lin- for Figure 6. Immunofluorescence, flow cytometric analyses, and calculations of the length of S phase were performed as described previously [7,20].
###end p 52
###begin title 53
Pathology
###end title 53
###begin p 54
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were monitored for disease development, as judged by increasing percentages of GFP+ cells with blast morphology in peripheral blood of transplanted animals, as well as symptoms, such as abnormal gait and labored breathing. Moribund animals were sacrificed and examined for tumors. Touch preps and tissue sections were obtained from spleen and liver.
###end p 54
###begin title 55
Supporting Information
###end title 55
###begin title 56
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
The Loss of E2f1 and E2f2 Promotes the Competitive Repopulation of the B Cell Lineage by Bcr-Abl-Expressing Progenitors
###end title 56
###begin p 57
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 30 31 30 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 118 127 118 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figures 2</xref>
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g004">4</xref>
###xml 207 208 207 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 250 257 250 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 275 276 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 280 281 280 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 301 308 301 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 348 355 348 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 413 417 413 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 417 418 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 418 419 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 419 420 419 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 695 702 695 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 705 709 703 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 709 710 707 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 710 711 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 711 712 709 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 717 724 715 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 733 737 729 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 737 738 733 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 738 739 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 739 740 735 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 866 867 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 487 492 <span type="species:ncbi:10090">mouse</span>
###xml 590 595 <span type="species:ncbi:10090">mouse</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
C-kit+ cells from either E2f1+2+ or DKO donor mice were transduced at low- and high-efficiency and transplanted as in Figures 2 and 4 (same experiments). The graph shows the changes in the percentages of GFP+ cells in the peripheral B220+ lineage of Bcr-Abl transduced E2f1+2+E2F1+ recipients (left), Bcr-Abl transduced DKO recipients (middle) and Bcr-Abl transduced DKO recipients supplemented with untransduced E2f1+2+ competitor progenitors (right). Each curve follows the individual mouse used in experiments with low (upper) and high (lower) transduction efficiency. Curves end if the mouse develops leukemia and is sacrificed prior to the next tail blood analysis. Surviving mice from the Bcr-Abl-->E2f1+2+ and Bcr-Abl-->DKO + E2f1+2+ competitors groups were bled at 180 and 240 d post-BMT (for low- and high-transduction experiments, respectively), and no GFP+ cells were detected above background in any recipient (unpublished data).
###end p 57
###begin p 58
(54 KB PPT).
###end p 58
###begin p 59
Click here for additional data file.
###end p 59
###begin title 60
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
\Inhibition of Apoptosis by Bcl2 Overexpression Does Not Provide a Competitive Advantage to DKO Relative to E2f1+2+ Progenitors
###end title 60
###begin p 61
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 5 6 5 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 6 7 6 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 450 454 450 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 454 455 454 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 455 456 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
E2f1+2+ or DKO BM cells were transduced with MSCV viruses expressing Bcl2 (with iresGFP), and then transplanted into lethally irradiated BALB/c mice. The mice were sacrificed at 3 wk post-transplant, and flow cytometric analysis of GFP and GR-1 expression in BM was performed. Initial infection efficiencies for both genotypes were similar. MSCV-expressed Bcl2 is functional, given that it conferred increased survival to BM progenitor cultures from E2f1+2+ and DKO mice (unpublished data).
###end p 61
###begin p 62
(54 KB PPT).
###end p 62
###begin p 63
Click here for additional data file.
###end p 63
###begin title 64
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2</italic>
###xml 71 74 71 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
HU Treatment Increases p190 Bcr-Abl-Mediated Leukemogenesis in the Rag2-/- Background
###end title 64
###begin p 65
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2</italic>
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 82 89 82 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 157 165 157 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 264 265 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">Mice</span>
(A) C-Kit+ cells from Rag2-/- BM (BALB/c congenic) were transduced with MSCV-p190 Bcr-Abl, and transplanted into lethally irradiated BALB/c recipients as in Figure 2. At 2 wk post-BMT, half of each group was switched to water containing HU. The average percent GFP+ in peripheral blood cells was 10%, and mice with similar percentages were segregated into the HU treated and untreated groups. Kaplan-Meier curves for transplanted mice are shown. Mice were sacrificed when moribund; all with splenomegaly and massive increases in GFP+ cells in the spleen and peripheral blood.
###end p 65
###begin p 66
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2</italic>
###xml 92 95 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 362 369 362 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 370 374 370 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2</italic>
###xml 374 377 374 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 604 605 604 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 644 645 644 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 721 722 721 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 745 746 745 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
(B) Representative flow cytometric plots are shown for recipients of Bcr-Abl-transduced Rag2-/- BM. Peripheral blood cells of the transplanted mice were analyzed for the expression of CD3 and IgM 2 wk post-BMT (before HU treatment). Cells expressing these markers (T and B cells) were almost undetectable in transplanted animals (left). Spleen cells from morbid Bcr-Abl/Rag2-/- (with and without HU) mice were analyzed for the expression of GFP, B220, Ter119, GR-1, and Thy1.2. Leukemias arising in untreated and HU-treated mice did not express B220 and Thy1.2 (unpublished data), but displayed many GR-1+ and Ter119+ cells (right; gated on GFP+ blast population). A similar blast population expressing both myeloid (GR-1+) and erythroid (Ter119+) markers was present in the one morbid non-HU treated recipient (unpublished data).
###end p 66
###begin p 67
(114 KB PPT).
###end p 67
###begin p 68
Click here for additional data file.
###end p 68
###begin title 69
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
Recipients of Bcr-Abl-Transduced Progenitors That Developed Leukemias With or Without HU Treatment Exhibited Splenomegaly and High Numbers of Leukocytic Blasts in Peripheral Blood
###end title 69
###begin p 70
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 94 102 94 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g007">Figure 7</xref>
###xml 336 337 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 362 369 362 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 726 733 726 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 773 774 773 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 830 835 <span type="species:ncbi:10090">mouse</span>
Recipients of vector or p190 Bcr-Abl transduced progenitors were treated or not with HU as in Figure 7 and sacrificed when morbid. Peripheral blood from the tail vein was drawn before sacrifice and analyzed for a complete blood count using a Cell-Dyn 1700 System. HU treatment of vector recipients did result in modest but significant (p < 0.05) leukopenia. For Bcr-Abl recipients with or without HU treatment, high peripheral leukocyte counts were evident, most of which were blasts (also confirmed microscopically), but the difference between HU-treated and untreated was not statistically significant. Following sacrifice, spleens were weighed. The increased spleen weight in HU-treated relative to untreated recipients of Bcr-Abl transduced progenitors is significant (p < 0.05). The average weight of a spleen from a healthy mouse is about 0.1 g.
###end p 70
###begin p 71
(40 KB PPT).
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin title 73
Leukemias That Developed in Untreated and HU-Treated Animals Were Transferable
###end title 73
###begin p 74
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 84 91 84 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
BM cells (5 x 103, 5 x 104, and 5 x 105) from morbid leukemic HU and non-HU treated Bcr-Abl BMT recipients were transplanted into BALB/c recipients. The fraction of transplanted mice that developed secondary leukemias is shown, and the time post-transplant that mice became morbid indicated in parentheses. Similar results were obtained with spleen cells from a different set of leukemic donors.
###end p 74
###begin p 75
(36 KB PPT).
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin title 77
Accession Numbers
###end title 77
###begin p 78
###xml 74 81 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f2</italic>
###xml 128 131 128 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
The GenBank () accession numbers of the genes discussed in this paper are Bcr-Abl (X06418), E2f1 (L21973), E2f2 (AK087452), and p53 (P04637).
###end p 78
###begin p 79
JD is supported by grants from the National Institutes of Health (NIH RO1 CA77314) and the American Cancer Society (RSG LIB-101051), and by a Scholar Award from the Leukemia and Lymphoma Society. CP is supported by a National Research Service Award (T32 CA 82086). RDC is supported by NIH grants U42 RR14905 and R01 CA89140. We would like to thank Drs. David Johnson, Erik Knudsen, and Rachel Rempel for their critical review of this manuscript, and Dr. Zonghan Dai for advice. We also thank K. Helm, C. Childs and M. Ashton of the Cancer Center Flow Cytometry Core (supported by grant 2 P30 CA 46934-09). JD dedicates this paper in the memory of Monika Weber, Kay Sutherland, and Atilio Ramos, relatives who succumbed to their leukemias.
###end p 79
###begin p 80
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 80
###begin title 81
References
###end title 81
###begin article-title 82
Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?
###end article-title 82
###begin article-title 83
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
###end article-title 83
###begin article-title 84
Chronic myeloid leukemia
###end article-title 84
###begin article-title 85
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia
###end article-title 85
###begin article-title 86
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Studying the pathogenesis of BCR-ABL+ leukemia in mice
###end article-title 86
###begin article-title 87
BCR/ABL regulates response to DNA damage: The role in resistance to genotoxic treatment and in genomic instability
###end article-title 87
###begin article-title 88
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice
###end article-title 88
###begin article-title 89
The E2F1-3 transcription factors are essential for cellular proliferation
###end article-title 89
###begin article-title 90
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Tumor induction and tissue atrophy in mice lacking E2F-1
###end article-title 90
###begin article-title 91
E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis
###end article-title 91
###begin article-title 92
The genetics of the E2F family of transcription factors: Shared functions and unique roles
###end article-title 92
###begin article-title 93
The E2F transcriptional network: Old acquaintances with new faces
###end article-title 93
###begin article-title 94
Causes of childhood leukaemia and lymphoma
###end article-title 94
###begin article-title 95
DNA damage from micronutrient deficiencies is likely to be a major cause of cancer
###end article-title 95
###begin article-title 96
Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells
###end article-title 96
###begin article-title 97
Characterization of homologous recombination induced by replication inhibition in mammalian cells
###end article-title 97
###begin article-title 98
Topoisomerase II inhibitor-related acute myeloid leukaemia
###end article-title 98
###begin article-title 99
Flk-2 is a marker in hematopoietic stem cell differentiation: A simple method to isolate long-term stem cells
###end article-title 99
###begin article-title 100
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse strain variability in the expression of the hematopoietic stem cell antigen Ly-6A/E by bone marrow cells
###end article-title 100
###begin article-title 101
A method to measure the duration of DNA synthesis and the potential doubling time from a single sample
###end article-title 101
###begin article-title 102
In vivo thymocyte maturation. BUdR labeling of cycling thymocytes and phenotypic analysis of their progeny support the single lineage model
###end article-title 102
###begin article-title 103
Regulation of DNA replication by ATR: Signaling in response to DNA intermediates
###end article-title 103
###begin article-title 104
The biology of CML blast crisis
###end article-title 104
###begin article-title 105
Clinical implications of p53 mutations
###end article-title 105
###begin article-title 106
Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal
###end article-title 106
###begin article-title 107
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Tumor spectrum analysis in p53-mutant mice
###end article-title 107
###begin article-title 108
Observation of antigen-dependent CD8(+) T-cell/ dendritic cell interactions in vivo
###end article-title 108
###begin article-title 109
The hallmarks of cancer
###end article-title 109
###begin article-title 110
Nature and nurture-Lessons from chemical carcinogenesis
###end article-title 110
###begin article-title 111
Incorporating basic nutrition science into health interventions for cancer prevention
###end article-title 111
###begin article-title 112
Folate status: Effects on pathways of colorectal carcinogenesis
###end article-title 112
###begin article-title 113
Relevance of folate metabolism in the pathogenesis of colorectal cancer
###end article-title 113
###begin article-title 114
Carcinogenesis, cancer therapy and chemoprevention
###end article-title 114
###begin article-title 115
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow
###end article-title 115
###begin article-title 116
###xml 152 156 <span type="species:ncbi:10090">mice</span>
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia
###end article-title 116
###begin article-title 117
###xml 114 118 <span type="species:ncbi:10090">mice</span>
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
###end article-title 117
###begin article-title 118
The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion
###end article-title 118
###begin article-title 119
Bcr-abl oncogene renders myeloid cell line factor independent: Potential autocrine mechanism in chronic myeloid leukemia
###end article-title 119
###begin article-title 120
###xml 59 64 <span type="species:ncbi:9606">human</span>
Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism
###end article-title 120
###begin article-title 121
Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression
###end article-title 121
###begin article-title 122
Targeted in vivo infection with a retroviral vector carrying the interleukin-3 (multi-CSF) gene leads to immortalization and leukemic transformation of primitive hematopoietic progenitor cells
###end article-title 122
###begin article-title 123
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
Retrovirus-mediated transfer and expression of the interleukin-3 gene in mouse hematopoietic cells result in a myeloproliferative disorder
###end article-title 123
###begin article-title 124
Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia
###end article-title 124
###begin article-title 125
Origins of chromosome translocations in childhood leukemia
###end article-title 125
###begin article-title 126
###xml 48 53 <span type="species:ncbi:9606">human</span>
BCR-ABL insufficiency for the transformation of human stem cells into CML
###end article-title 126
###begin article-title 127
Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia
###end article-title 127
###begin article-title 128
###xml 85 93 <span type="species:ncbi:9606">children</span>
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
###end article-title 128
###begin article-title 129
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea
###end article-title 129
###begin article-title 130
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
###end article-title 130
###begin article-title 131
The treatment of inflammatory arthritis with methotrexate in clinical practice: Treatment duration and incidence of adverse drug reactions
###end article-title 131
###begin article-title 132
###xml 19 23 <span type="species:ncbi:10090">mice</span>
E2F-1 functions in mice to promote apoptosis and suppress proliferation
###end article-title 132
###begin article-title 133
###xml 20 24 <span type="species:ncbi:10090">mice</span>
Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity
###end article-title 133
###begin title 134
Abbreviations
###end title 134
###begin p 135
acute lymphoblastic leukemia
###end p 135
###begin p 136
bone marrow
###end p 136
###begin p 137
bone marrow transplantation
###end p 137
###begin p 138
bromodeoxyuridine
###end p 138
###begin p 139
chronic myelogenous leukemia
###end p 139
###begin p 140
oligomerization domain of p53
###end p 140
###begin p 141
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 11 14 11 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
E2f1-/-E2f2-/-
###end p 141
###begin p 142
dominant negative p53 mutant
###end p 142
###begin p 143
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 11 14 11 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
E2f1+/-E2f2+/-
###end p 143
###begin p 144
green fluorescent protein
###end p 144
###begin p 145
hematopoietic stem cell
###end p 145
###begin p 146
hydroxyurea
###end p 146
###begin p 147
interleukin
###end p 147
###begin p 148
lineage negative
###end p 148
###begin p 149
###xml 0 5 <span type="species:ncbi:10090">mouse</span>
mouse stem cell virus
###end p 149
###begin p 150
propidium iodide
###end p 150
###begin p 151
standard error
###end p 151
###begin title 152
Figures
###end title 152
###begin title 153
Experimental Design
###end title 153
###begin title 154
The Expression of Bcr-Abl Provides a Competitive Advantage to DKO Progenitors
###end title 154
###begin p 155
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 247 254 247 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 317 321 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 323 324 323 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 362 363 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 424 431 424 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 443 447 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 447 448 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 449 450 449 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 502 506 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 506 507 506 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 508 509 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 530 531 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 581 582 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 633 634 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 656 657 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 771 775 771 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 775 776 775 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 776 777 776 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 777 778 777 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Purified c-Kit+ cells from either E2f1+2+ or DKO donor mice (pooled sets of littermates) were transduced with MSCV-expressing p190 Bcr-Abl and GFP or GFP only (vector), and transplanted into lethally irradiated BALB/c recipients. The same pool of Bcr-Abl transduced DKO progenitors was either mixed with untransduced E2f1+2+ competitor progenitors ("DKO + E2F1+2+ competitors") or with untransduced DKO progenitors ("DKO"). Bcr-Abl-transduced E2f1+2+ progenitors similarly were mixed with untransduced E2f1+2+ progenitors ("E2F1+2+"). Specifically, each recipient received 2.5 x 105 untransduced whole BM cells combined with 1.2 x 106 MSCV-transduced c-Kit+ cells. Initial infection efficiencies measured for the whole c-Kit-enriched population were 5.1% and 3.75% among E2f1+2+, and 4.73% and 3.4% among DKO progenitors for Bcr-Abl and vector, respectively. Tail blood isolated at 3 wk post-BMT was analyzed for the expression of GFP and B220 (upper bar graph; B-cell lineage) or GR-1 (lower bar graph; myeloid lineage) by flow cytometry.
###end p 155
###begin p 156
###xml 39 43 <span type="species:ncbi:10090">mice</span>
(A) Each bar represents data from five mice with standard error (SE) indicated, and statistical significance determined using Student's unpaired t-test (for all figures in this paper).
###end p 156
###begin p 157
(B) Representative flow cytometric profiles of peripheral B cells are shown, with the percentages of peripheral blood cells expressing both GFP and B220 indicated.
###end p 157
###begin p 158
###xml 211 212 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 279 280 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 285 286 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 362 363 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 368 369 368 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 459 466 459 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 478 482 478 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 482 483 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 483 484 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 484 485 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 533 534 533 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 539 540 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 545 546 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(C) BM cells were analyzed by flow cytometry for the expression of Lin antigens, Sca1, Flk2 and GFP. Lin antigens included GR-1, B220, Ter119, CD3, and CD4. Cells analyzed in the profiles shown were gated as Lin- Flk2-. The upper right quadrant represents progenitor-enriched Lin- Flk2- Sca1+ cells expressing either Bcr-Abl or vector, and the percentages of Lin- Flk2- cells that express Sca1 and/or GFP are indicated. In multiple experiments, recipients of Bcr-Abl transduced E2f1+2+ cells exhibited reduced percentages of GFP- Lin- Flk2- Sca1+ cells (the upper left quadrant) relative to vector controls, a phenomenon that we do not currently understand.
###end p 158
###begin title 159
Bcr-Abl Restores S Phase Progression in DKO Progenitors
###end title 159
###begin p 160
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 109 117 109 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
Wild-type or DKO donor mouse c-Kit+ cells were transduced with MSCV-Bcr-Abl or vector and transplanted as in Figure 2 but at higher efficiency.
###end p 160
###begin p 161
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 253 254 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 304 305 304 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 306 307 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 329 336 329 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
(A) Recipients were injected 3 wk post-transplant with BrdU and spleen B cell and myeloid progenitors (combined) isolated by flow sorting, separating GFP+ from GFP-. Immunofluorescence for BrdU together with PI staining for DNA content are shown for GFP- cells (internal control) and GFP+ cells from E2f1+2+ or DKO recipients of Bcr-Abl-transduced stem cells. The percentages of cells with S phase DNA content but without significant BrdU incorporation (in the small square) are indicated.
###end p 161
###begin p 162
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(B) The histograms shown in the insets in (A) plot the DNA content of cells gated as BrdU+, which are used to calculate the average lengths of S phase (from two experiments, +/- SE).
###end p 162
###begin title 163
###xml 5 8 5 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f</italic>
E2f1/E2f2 Loss Promotes Bcr-Abl-Mediated Leukemias
###end title 163
###begin p 164
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 15 16 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 70 77 70 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 101 109 101 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 285 293 285 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 350 358 350 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 428 429 428 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 556 557 556 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 576 577 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 612 613 612 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 613 620 613 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 893 900 893 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 942 949 942 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 951 955 951 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 955 956 955 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 956 957 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 957 958 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 960 961 960 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 982 983 982 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1006 1013 1006 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 1020 1024 1020 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2f1</italic>
###xml 1024 1025 1024 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1025 1026 1025 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 1026 1027 1026 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1041 1042 1041 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1060 1061 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 533 538 <span type="species:ncbi:10090">mouse</span>
###xml 697 701 <span type="species:ncbi:10090">Mice</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
(A and B) E2f1+2+ or DKO mouse c-Kit+ cells were transduced with MSCV-Bcr-Abl and transplanted as in Figure 2, except that in (B) a higher initial transduction efficiency was obtained (23.2% for E2f1+2+ and 24.1% for DKO). Initial transduction efficiencies for (A) were the same as in Figure 2. Untransduced competitors were included as described in Figure 2, except that for the experiments shown in (B), competitors were c-Kit+-purified BM cells cultured in parallel to the transduced cultures but not infected, and each recipient mouse received 1.5 x 105 untransduced c-Kit+ competitors combined with 1.4 x 106Bcr-Abl-transduced progenitors. Kaplan-Meier curves are shown for both experiments. Mice were sacrificed when moribund, all with splenomegaly and lymphadenopathy. No mice transplanted with vector-expressing cells developed leukemia (unpublished data). The Kaplan-Meier curves for Bcr-Abl/DKO are statistically different from the Bcr-Abl/ E2f1+2+ (p < 0.001 for [A] and p < 0.0001 for [B]) and Bcr-Abl/DKO + E2f1+2+ competitors (p < 0.001 for [A], p < 0.02 for [B]) curves.
###end p 164
###begin p 165
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 266 273 266 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 416 417 416 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
(C) Peripheral blood, spleen, and BM from morbid leukemic Bcr-Abl BMT mice or from healthy vector BMT mice (from [B]) were analyzed for the expression of the indicated antigens and GFP by flow cytometry. Peripheral blood was analyzed 21 d post-BMT. The recipient of Bcr-Abl/DKO cells was sacrificed at 23 d and other recipients sacrificed at 29 d post-BMT. The mean fluorescence intensities (mfi) for peripheral B220+ cells are indicated.
###end p 165
###begin title 166
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
HU Promotes the Competitive Expansion of Bcr-Abl+ Blood Progenitors Ex Vivo
###end title 166
###begin p 167
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 385 386 384 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sub>
###xml 397 404 396 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 404 405 403 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(A) BALB/c c-Kit+ BM cells were transduced with MSCV-Bcr-Abl or vector and cultured in stem cell medium with HU (0, 5, 10, 25, 50, or 100 muM) added starting at day 3. Flow cytometric analysis of GFP expression and total cell counting in cultures were performed every 3-4 d. The changes in GFP percentages in vector and Bcr-Abl cultures (upper graphs) and the cumulative expansion (loge scale) of Bcr-Abl+ and vector cells (lower graphs) during HU treatment were plotted.
###end p 167
###begin p 168
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030401-b35">35</xref>
###xml 218 225 218 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(B) The percentages of cells expressing Bcr-Abl (day 13) as well as the mean fluorescence intensities (mfi) for the GFP+ population, which has been shown to reflect Bcr-Abl protein expression [35], are indicated. Most Bcr-Abl+ cells were c-Kit+CD34+, with or without HU treatment. HU treatment did not affect the intensity of GFP in vector cells (unpublished data).
###end p 168
###begin title 169
HU Selects for Bcr-Abl Expression Within Hematopoietic Progenitor Pools In Vivo
###end title 169
###begin p 170
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
BALB/c c-Kit+ BM cells were transduced with the indicated retroviruses, and transplanted into sublethally irradiated BALB/c recipients. At 2 wk post-BMT, half of each group was switched to water containing HU.
###end p 170
###begin p 171
###xml 93 101 93 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g002">Figure 2</xref>
###xml 190 191 190 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 239 240 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(A) BM cells were analyzed for the expression of Lin antigens, Sca1, and GFP as described in Figure 2C on days 5 and 8 of HU treatment. Cells analyzed in the profiles shown were gated as Lin-. The percentages of the progenitor enriched Lin- Sca1+ population that expressed vector or Bcr-Abl are indicated in the upper right corners (underlined).
###end p 171
###begin p 172
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 155 163 155 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g003">Figure 3</xref>
###xml 202 203 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
(B) Four days after switching to HU water (or not), mice were injected with BrdU, and spleen GFP+ and GFP- Lin- progenitors isolated by flow sorting as in Figure 3. BrdU incorporation is detected in GFP- cells (internal control) and GFP+ cells, and the calculated average lengths of S phase from two experiments is shown in the graph.
###end p 172
###begin title 173
HU Treatment Enhances Bcr-Abl-Mediated Leukemogenesis
###end title 173
###begin p 174
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 74 82 74 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g006">Figure 6</xref>
Bcr-Abl BMT recipients were generated and treated with HU as described in Figure 6.
###end p 174
###begin p 175
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 188 195 188 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 252 259 252 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 278 279 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 292 293 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 357 358 357 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 572 573 572 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 576 577 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 596 597 596 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 600 601 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 397 401 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">Mice</span>
(A-B) Kaplan-Meier curves for vector (A), p190 Bcr-Abl (A), or p210 Bcr-Abl (B) transduced stem cell-transplanted mice with or without HU treatment are shown. The curves for p190 and p210 Bcr-Abl with HU are statistically different from the respective Bcr-Abl-untreated curves (p < 0.001 and p < 0.05, respectively). For (A) and (B), the average percent GFP+ in peripheral blood cells was 3%, and mice with similar percentages were segregated into the HU-treated and untreated groups. Mice were sacrificed when moribund, all with splenomegaly and massive increases in B220+GFP+ (for p190) or GR-1+GFP+ (for p210) cells in the spleen and peripheral blood.
###end p 175
###begin p 176
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 82 90 82 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030401-g006">Figure 6</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
(C) Peripheral blood from morbid p190 Bcr-Abl-BMT mice (with or without HU, as in Figure 6) or from a healthy vector BMT mouse was analyzed for B220 and GR-1 expression by flow cytometry.
###end p 176
###begin p 177
###xml 285 292 285 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 505 506 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 525 526 525 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 609 616 607 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 616 617 614 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 740 747 738 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcr-Abl</italic>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
(D) BM cells from morbid p190 BMT mice were analyzed for the expression of c-Kit, CD34, CD43, B220, with side scatter and forward scatter (reflects cell size) as indicated. The dashed oval indicates the typical position of normal BM pre/pro-B-cells. All leukemic BM cells in untreated Bcr-Abl recipients expressed B220 and CD43 as shown in the upper panels. Leukemic BM cells from HU treated mice generally expressed less B220 (despite B220 expression in peripheral cells; see (A) and displayed more c-Kit+ and many more CD34+ cells. Percentages shown are averages (+/- SD) for three mice for each group. Two Bcr-Abl+ mice treated with HU that developed leukemia late (7 and 10 wk post-BMT) displayed an immunophenotype more similar to the Bcr-Abl-untreated mice.
###end p 177
###begin title 178
The Inhibition of p53 Provides a Competitive Advantage for DKO, but Not Wild-Type, BM Progenitors
###end title 178
###begin p 179
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(A) Wild-type or DKO BM cells were transduced with MSCV-DNp53, MSCV-DDp53, or vector, and transplanted into lethally irradiated BALB/c recipients. At 2 wk post-BMT, the percentage of GFP+ cells among peripheral blood GR-1+ cells was determined by flow cytometry. The contribution of GFP+ cells after 2 wk relative to the initial infection efficiency is shown. Initial infection efficiencies for each virus were similar for the two BM genotypes.
###end p 179
###begin p 180
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 289 290 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
(B) Genetic disruption of p53 provides a proliferative advantage in the DKO but not wild-type background. The indicated mixtures of freshly harvested BM were used to reconstitute the hematopoietic system of lethally irradiated recipient BALB/c mice. At 6 wk post-BMT, the percentage of GFP+ nucleated cells in peripheral blood was determined by flow cytometry and fold expansion was determined relative to the initial mixture.
###end p 180
###begin title 181
The Poor Competition Model
###end title 181
###begin p 182
In a wild-type, healthy progenitor cell pool, potentially oncogenic mutations (represented as a red "X" in a cell) will often provide little or no advantage in the short term, and may even be disadvantageous (top images). In contrast, in a replication-impaired hematopoietic system (bottom images), acquisition of some oncogenic mutations should provide a selective advantage by partly or fully restoring cell cycle progression, even when the same mutation might be disadvantageous in a wild-type pool. The preferential expansion of the mutated population increases the target size and thus the chances for additional mutations and cancer. In this figure, the rectangle indicates the limited niche size, implying competition for contacts and growth factors. The thickness of curved arrows indicates proliferative ability.
###end p 182
###begin p 183
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. GB and JVD conceived and designed the experiments. GB, AM, and CCP performed the experiments. GB and JVD analyzed the data. RDC performed pathological analyses of leukemias. GB and JVD wrote the paper.
###end p 183
###begin p 184
Citation: Bilousova G, Marusyk A, Porter CC, Cardiff RD, DeGregori J (2005) Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol 3(12): e401.
###end p 184

